Nurix Announces DeTIL-0255 Scientific Presentations at the 37th Annual Meeting of the Society ...
Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with hematologic malignancies and solid tumors, presented preclinical data supporting the utility of its CBL-B inhibitors to enhance cell therapy at the 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC), which is being held November 8 – 12th in Boston. Nurix also announced the successful completion of the safety run-in portion of the ongoing Phase 1 trial of DeTIL-0255 in patients with advanced gynecologic malignancies and revealed that it has received feedback from the FDA regarding the potential combination of DeTIL-0255 with the oral CBL-B inhibitor NX-1607. The FDA feedback, the preliminary safety profile of DeTIL-0255, and the potential benefits of combining DeTIL-0255 with in vivo pharmacologic inhibition of CBL-B with NX-1607 provide a path for a potential future combination trial to explore whether inhibiting CBL-B both ex vivo and in vivo may enhance the anti-tumor potential of adoptive cell therapy
SAN FRANCISCO, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with hematologic malignancies and solid tumors, presented preclinical data supporting the utility of its CBL-B inhibitors to enhance cell therapy at the 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC), which is being held November 8 – 12th in Boston. Nurix also announced the successful completion of the safety run-in portion of the ongoing Phase 1 trial of DeTIL-0255 in patients with advanced gynecologic malignancies and revealed that it has received feedback from the FDA regarding the potential combination of DeTIL-0255 with the oral CBL-B inhibitor NX-1607. The FDA feedback, the preliminary safety profile of DeTIL-0255, and the potential benefits of combining DeTIL-0255 with in vivo pharmacologic inhibition of CBL-B with NX-1607 provide a path for a potential future combination trial to explore whether inhibiting CBL-B both ex vivo and in vivo may enhance the anti-tumor potential of adoptive cell therapy.
“We believe that our portfolio of first-in-class CBL-B inhibitors has the potential to improve outcomes for patients with solid tumors and enhance the field of cell therapy,” said Robert J. Brown, M.D., executive vice president of clinical development at Nurix. “Pending successful completion of Nurix’s NX-1607 Phase 1a dose escalation trial, we envision expanding the use of NX-1607 as a single agent in selected indications in 2023. We also can see a path to exploring the potential for a combination strategy with DeTIL-0255 in accordance with recent feedback from the FDA.”
The Phase 1 safety run-in includes three patients with advanced epithelial ovarian cancer (EOC) who have been dosed with DeTIL-0255 and have cleared the initial safety evaluation. Expansion of the Phase 1 trial will be postponed, pending potential inclusion of NX-1607 in future cohorts.
Summary of DeTIL-0255-related data presented at the SITC meeting:
